Skip to main content
. Author manuscript; available in PMC: 2016 Jan 30.
Published in final edited form as: Circ Res. 2014 Nov 5;116(3):448–455. doi: 10.1161/CIRCRESAHA.116.305360

Figure 1. Prognostic Value of Plasma trimethylamine N-oxide (TMAO) Levels in the CKD Cohort.

Figure 1

In a cohort of stable cardiac patients undergoing elective diagnostic coronary evaluation, subjects with underlying Stage 3+ chronic kidney disease demonstrated higher levels of fasting plasma TMAO than those with no CKD (p<0.01, Panel A). Increasing quartiles fasting plasma TMAO levels portend increased risk for all-cause mortality at 5 years in patients with CKD (n=521, Panel B).